Cullinan Therapeutics Inc
CGEM
Market Cap$452.64M
Close$
$1.50
81% downside
Current Fair Value
81% downsideOvervalued by 81% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $452.64 Million |
|---|---|
| Enterprise Value | $360.72 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.11 |
| Beta | -0.04 |
| Outstanding Shares | 58,905,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.53 |
|---|---|
| PEG | -8.27 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.73 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | -0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...